Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of nasopharyngeal cancer (a non-keratinizing type, confirmed by tissue testing)
• People whose cancer has been staged as Stage III or Stage IVA using a standard staging system (AJCC 8th edition, specific tumor and lymph node categories, with no spread to distant organs)
• People who are generally well enough to carry out daily activities with only minor limitations (a standard health performance score of 0 or 1)
• People whose blood counts are within acceptable ranges — including white blood cells, red blood cells, and platelets — as measured by blood tests
• People whose liver function tests (ALT, AST, and bilirubin) are within acceptable ranges as measured by blood tests
• People whose kidneys are functioning well enough, based on a calculated measure of kidney filtration rate (at least 60 ml/min)
• People who are willing to sign a written consent form after being informed about the nature of the study
• People who are able to have children and are sexually active must be willing to use effective contraception during treatment and for one year after the last dose; this applies to both women who could become pregnant and men who are sexually active with women who could become pregnant

Who may not be able to join:

• People who are younger than 18 or older than 70 years of age
• People who test positive for Hepatitis B surface antigen with a viral load above a certain level
• People who test positive for Hepatitis C antibodies
• People who have an active autoimmune disease (certain exceptions may apply, such as type 1 diabetes, thyroid conditions managed with hormone replacement, or skin conditions not requiring systemic treatment — confirm with trial site)
• People who have a known history of a lung condition called interstitial lung disease
• People who have needed steroid medication (above a low dose threshold) or other immune-suppressing treatments within 28 days before signing consent; low-dose, inhaled, or topical steroids may be acceptable (confirm with trial site)
• People who have received a live vaccine within 30 days before signing consent, or who are expected to receive one in the near future
• People who are pregnant or breastfeeding
• People who have a history of other cancers, with some exceptions such as certain skin cancers and papillary thyroid cancer (confirm with trial site)
• People who have a known allergy to large protein-based medicines or to any ingredient in the study drug sintilimab
• People who have a known history of HIV infection
• People who have other serious conditions such as symptomatic heart failure, unstable angina, recent heart attack, active infections needing systemic treatment, mental illness, or other social or medical factors that the trial doctor considers would interfere with participation

Important: Always verify eligibility with the trial site directly before applying.